NCT01474330View on ClinicalTrials.gov

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 1, 2011

Primary Completion Date

October 1, 2011

Study Completion Date

October 1, 2011

Conditions
Healthy
Interventions
DRUG

Pomalidomide

0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions

DRUG

Placebo

Placebo capsule

Trial Locations (1)

78744

PPD Phase I Clinic, Austin

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY